Introduction: Why Device-Ready Biologics Require a Different CDMO Model Biologic medicines have evolved far beyond the laboratory proteins and antibodies that defined the early years of modern biotechnology. Today’s biologics are increasingly sophisticated therapeutic systems: high-concentration monoclonal antibodies, enzyme replacement therapies, cytokine modulators, and recombinant proteins designed for chronic disease management. These therapies often require […]

India has no shortage of contract manufacturers. Facilities exist everywhere. Capacity is advertised loudly. Certifications are listed endlessly. Yet sponsors who have actually tried to move complex programs through Indian CDMOs know a quieter truth: capacity is not capability, and scale without discipline is a liability. Dharma Biologics was built as a response to this […]